Patents by Inventor Cesar Castro

Cesar Castro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11125745
    Abstract: Target analyte detection devices include a housing having a potentiostat and a microcontroller coupled to the potentiostat. The device also includes a substrate having a plurality of electrodes on a first surface of the substrate. A first set of electrodes of the plurality of electrodes defines a first sample detection region. The substrate is removably attachable to the housing such that the first set of electrodes is coupled to the potentiostat upon attaching the substrate to the housing. The device also includes a magnet assembly couplable to a second surface of the substrate. The magnet assembly includes a magnet positioned in the magnet assembly such that a magnetic field from the magnet extends through the substrate and the first set of electrodes into an area above the first sample detection region upon coupling the magnet assembly to the substrate.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: September 21, 2021
    Assignees: The General Hospital Corporation, The Brigham and Women's Hospital, Inc.
    Inventors: Hakho Lee, Ralph Weissleder, Sangmoo Jeong, Jongmin Park, Cesar Castro, Hsing-Ying Lin, Jamil Azzi
  • Patent number: 11078191
    Abstract: This invention relates to an active metabolite of 5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimindin-4-amine that modulates the activity of adenosine A2a receptor. In particular, the present invention relates to pharmaceutical compositions comprising 1-(4-amino-5-bromo-6-(1H-pyrazol-1-yl)-pyrimidin-2-yl)-1H-pyrazol-4-ol, as well as processes for its preparation and its use in the treatment of cancer alone of in combination with one or more immunotherapeutic agents.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: August 3, 2021
    Assignees: Novartis AG, Palobiofarma S.L.
    Inventors: Sanela Bilic, Juan Alberto Camacho Gomez, John Scott Cameron, Julio Cesar Castro-Palomino Laria, Danny Roland Howard, Jr.
  • Publication number: 20210145831
    Abstract: This application relates to various crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimidin-4-amine and salt thereof, as well as compositions and methods of using the same. In some embodiments the crystalline forms also contain water (“hydrates”). These materials are useful in the treatment of various diseases, including carcinomas, specifically lung cancer and more specifically non-small cell lung cancer.
    Type: Application
    Filed: January 25, 2021
    Publication date: May 20, 2021
    Inventors: Kai CUI, Julio Cesar CASTRO-PALOMINO LARIA, Weiyong KONG
  • Publication number: 20210080390
    Abstract: The disclosure features systems and methods for measuring and diagnosing target constituents bound to labeling particles in a sample. The systems include a radiation source, a sample holder, a detector configured to obtain one or more diffraction patterns of the sample each including information corresponding to optical properties of sample constituents, and an electronic processor configured to, for each of the one or more diffraction patterns: (a) analyze the diffraction pattern to obtain amplitude information and phase information corresponding to the sample constituents; (b) identify one or more particle-bound target sample constituents based on at least one of the amplitude information and the phase information; and (c) determine an amount of at least one of the particle-bound target sample constituents in the sample based on at least one of the amplitude information and the phase information.
    Type: Application
    Filed: July 27, 2020
    Publication date: March 18, 2021
    Inventors: Ralph Weissleder, Hakho Lee, Hyungsoon Im, Cesar Castro
  • Patent number: 10933064
    Abstract: This application relates to various crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimidin-4-amine and salt thereof, as well as compositions and methods of using the same. In some embodiments the crystalline forms also contain water (“hydrates”). These materials are useful in the treatment of various diseases, including carcinomas, specifically lung cancer and more specifically non-small cell lung cancer.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: March 2, 2021
    Assignees: Novartis AG, Palobiofarma S.L.
    Inventors: Kai Cui, Julio Cesar Castro-Palomino Laria, Weiyong Kong
  • Patent number: 10724948
    Abstract: The disclosure features systems and methods for measuring and diagnosing target constituents bound to labeling particles in a sample. The systems include a radiation source, a sample holder, a detector configured to obtain one or more diffraction patterns of the sample each including information corresponding to optical properties of sample constituents, and an electronic processor configured to, for each of the one or more diffraction patterns: (a) analyze the diffraction pattern to obtain amplitude information and phase information corresponding to the sample constituents; (b) identify one or more particle-bound target sample constituents based on at least one of the amplitude information and the phase information; and (c) determine an amount of at least one of the particle-bound target sample constituents in the sample based on at least one of the amplitude information and the phase information.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: July 28, 2020
    Assignee: The General Hospital Corporation
    Inventors: Ralph Weissleder, Hakho Lee, Hyungsoon Im, Cesar Castro
  • Patent number: 10712343
    Abstract: This invention relates to methods for diagnosing cancer, e.g., cancer of epithelial origin, by detecting the presence of tumor cells in a sample, based (at least in some embodiments) on the quantification of levels of four biomarkers, MUC1, EGFR, EpCAM, and HER2. In some embodiments, the methods are performed using diagnostic magnetic resonance (DMR), e.g., with a portable relaxometer or MR imager.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: July 14, 2020
    Assignee: The General Hospital Corporation
    Inventors: Ralph Weissleder, Hakho Lee, Cesar Castro
  • Publication number: 20200163963
    Abstract: This application relates to various crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimidin-4-amine and salt thereof, as well as compositions and methods of using the same. In some embodiments the crystalline forms also contain water (“hydrates”). These materials are useful in the treatment of various diseases, including carcinomas, specifically lung cancer and more specifically non-small cell lung cancer.
    Type: Application
    Filed: May 30, 2018
    Publication date: May 28, 2020
    Inventors: Kai CUI, Julio Cesar CASTRO-PALOMINO LARIA, Weiyong KONG
  • Patent number: 10620628
    Abstract: An Unmanned Air Vehicle control station, comprising critical systems implementing safety involved functions, non-critical systems implementing non-safety involved functions and a gateway computer. The critical systems comprise at least two redundant critical computers, a redundant critical network and critical back-up network, and at least two redundant UAV-specific computers that implement UAV-specific functions and communicate with the UAV, wherein the at least two critical computers and the at least two UAV-specific computers are connected to the critical network and to the critical back-up network. The non-critical systems comprise at least one non-critical computer, and a non-critical network, wherein the at least one non-critical computer is connected to the non-critical network.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: April 14, 2020
    Assignee: AIRBUS DEFENCE AND SPACE S.A.
    Inventors: Francisco Javier Ramos Salas, César Castro Gómez, Aníbal Fernández Vázquez
  • Patent number: 10561653
    Abstract: The present invention relates to 5-bromo-2,6-di-(1H-pyrazol-1-yl)pyrimidin-4-amine, its pharmaceutically acceptable salts and co-crystals thereof and to pharmaceutical compositions comprising said compounds for use in the treatment of cancer.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: February 18, 2020
    Assignees: Novartis AG, Palobiofarma, S.L.
    Inventors: Sanela Bilic, Juan Alberto Camacho Gomez, John Scott Cameron, Julio Cesar Castro-Palomino Laria, Danny Roland Howard, Jr.
  • Patent number: 10557847
    Abstract: Disclosed herein are compositions and methods for exosome detection with high sensitivity by using a nano-plasmonic sensor. The nano-plasmonic sensor comprises a plurality of nanoapertures suitable for transmission measurements. The detection sensitivity is on the order of 104-fold higher than western blotting and 102-fold higher than enzyme-linked immunosorbent assay (ELISA). A portable imaging system is also disclosed, enabling rapid and high-throughput detection of exosomes. The nano-plasmonic sensor and imaging system can be useful in diagnostics.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: February 11, 2020
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Ralph Weissleder, Hakho Lee, Hyungsoon Im, Cesar Castro
  • Publication number: 20190359600
    Abstract: This invention relates to an active metabolite of 5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimindin-4-amine that modulates the activity of adenosine A2a receptor. In particular, the present invention relates to pharmaceutical compositions comprising 1-(4-amino-5-bromo-6-(1H-pyrazol-1-yl)-pyrimidin-2-yl)-1H-pyrazol-4-ol, as well as processes for its preparation and its use in the treatment of cancer alone of in combination with one or more immunotherapeutic agents.
    Type: Application
    Filed: February 8, 2018
    Publication date: November 28, 2019
    Inventors: Sanela BILIC, Juan Alberto CAMACHO GOMEZ, John Scott CAMERON, Julio Cesar CASTRO-PALOMINO LARIA, Danny Roland HOWARD
  • Patent number: 10329256
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: June 25, 2019
    Assignee: Oryzon Genomics, S.A.
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Àngeles Estiarte Martinez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
  • Publication number: 20190113451
    Abstract: The disclosure features systems and methods for measuring and diagnosing target constituents bound to labeling particles in a sample. The systems include a radiation source, a sample holder, a detector configured to obtain one or more diffraction patterns of the sample each including information corresponding to optical properties of sample constituents, and an electronic processor configured to, for each of the one or more diffraction patterns: (a) analyze the diffraction pattern to obtain amplitude information and phase information corresponding to the sample constituents; (b) identify one or more particle-bound target sample constituents based on at least one of the amplitude information and the phase information; and (c) determine an amount of at least one of the particle-bound target sample constituents in the sample based on at least one of the amplitude information and the phase information.
    Type: Application
    Filed: July 2, 2018
    Publication date: April 18, 2019
    Inventors: Ralph Weissleder, Hakho Lee, Hyungsoon Im, Cesar Castro
  • Patent number: 10253017
    Abstract: The present invention relates to novel pyridine derivatives of formula (I): as A2B adenosine receptor antagonists and ligands of MT3 melatonin receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by antagonizing the adenosine A2B receptor and by inhibition of MT3 melatonin receptor, such as respiratory disease, metabolic disorders, neurological disorders and cancer.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: April 9, 2019
    Assignee: PALOBIOFARMA, S.L.
    Inventors: Julio Cesar Castro-Palomino Laria, Juan Alberto Camacho Gómez, Adela Mendoza Lizaldez
  • Patent number: 10214477
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: February 26, 2019
    Assignee: Oryzon Genomics S.A.
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Àngeles Estiarte Martinez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
  • Publication number: 20180354902
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
    Type: Application
    Filed: March 5, 2018
    Publication date: December 13, 2018
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Angeles Estiarte Martinez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
  • Publication number: 20180228802
    Abstract: The present invention relates to 5-bromo-2,6-di-(1H-pyrazol-1-yl)pyrimidin-4-amine, its pharmaceutically acceptable salts and co-crystals thereof and to pharmaceutical compositions comprising said compounds for use in the treatment of cancer.
    Type: Application
    Filed: August 10, 2016
    Publication date: August 16, 2018
    Applicants: NOVARTIS AG, PALOBIOFARMA, S.L.
    Inventors: Sanela BILIC, Juan Alberto CAMACHO GOMEZ, John Scott CAMERON, Julio Cesar CASTRO-PALOMINO LARIA, Danny Roland HOWARD, Jr.
  • Patent number: 10012589
    Abstract: The disclosure features systems and methods for measuring and diagnosing target constituents bound to labeling particles in a sample. The systems include a radiation source, a sample holder, a detector configured to obtain one or more diffraction patterns of the sample each including information corresponding to optical properties of sample constituents, and an electronic processor configured to, for each of the one or more diffraction patterns: (a) analyze the diffraction pattern to obtain amplitude information and phase information corresponding to the sample constituents; (b) identify one or more particle-bound target sample constituents based on at least one of the amplitude information and the phase information; and (c) determine an amount of at least one of the particle-bound target sample constituents in the sample based on at least one of the amplitude information and the phase information.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: July 3, 2018
    Assignee: The General Hospital Corporation
    Inventors: Ralph Weissleder, Hakho Lee, Hyungsoon Im, Cesar Castro
  • Publication number: 20180150075
    Abstract: An Unmanned Air Vehicle control station, comprising critical systems implementing safety involved functions, non-critical systems implementing non-safety involved functions and a gateway computer. The critical systems comprise at least two redundant critical computers, a redundant critical network and critical back-up network, and at least two redundant UAV-specific computers that implement UAV-specific functions and communicate with the UAV, wherein the at least two critical computers and the at least two UAV-specific computers are connected to the critical network and to the critical back-up network. The non-critical systems comprise at least one non-critical computer, and a non-critical network, wherein the at least one non-critical computer is connected to the non-critical network.
    Type: Application
    Filed: November 28, 2017
    Publication date: May 31, 2018
    Inventors: Francisco Javier RAMOS SALAS, César CASTRO GÓMEZ, Aníbal FERNÁNDEZ VÁZQUEZ